![]() ![]() This is only the beginning of advancements in concussion testing as we continue to research future indications for both adults and children.” ![]() This lab test for concussion will be a game changer for concussion assessment in hospitals, giving clinicians an objective tool to quickly assess a possible brain injury, triage patients, and reduce the number of unnecessary CT scans-giving people who test negative peace of mind. Notably, clinicians can receive a reliable result from the test in 18 minutes, with a 96.7% sensitivity and 99.4% negative predictive value.īeth McQuiston, MD, medical director in Abbott's diagnostics business, told NeurologyLive ®, “We are seeing the beginning of the future in how concussions are evaluated. The test measures 2 biomarkers in the blood plasma and serum, ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), both of which are tightly correlated to brain injury. The test will be available in hospitals to quickly assist clinicians in assessing patients with mild TBIs, known as concussions, in an objective way and help develop the next steps of care for patients. Overall, the report indicates Abbott's remarkable revenue growth.According to news from Abbott, the FDA cleared its Alinity i laboratory traumatic brain injury (TBI) blood test, the first commercially available test of its kind. It provides reliable test results in just minutes. ![]() This FDA-approved system delivers lab-accurate testing for Blood Gases, Electrolytes, Chemistries, Coagulation, Hematology, Glucose, and Cardiac Markers (cTnI). When it comes to point-of-care, sales growth in the quarter was driven by continued adoption of Abbott's i-STAT handheld system in the US and strong growth internationally. It was also noted that the firm is seeing continued strong growth in infectious disease testing, which is its core area of focus in the molecular diagnostics market. The CEO of Abbott says, "Point-of-care testing remains an attractive growth segment within the in vitro diagnostics market, and the acquisition of Alere will significantly expand our diagnostics presence and leadership in that space." Based on the amended terms, the company will pay $51 per share to acquire Alere for a new total price of about $5.3 billion, which is less than the original purchase price of around $5.8 billion proposed in February 2016. Abbott had agreed to amend the existing terms of an agreement to acquire Alere. Point-of-care revenues were $135 million, up 8 percent from $125 millionĪbbott's acquisition of Alere was in the news recently.Molecular revenues were $112 million, up 4 percent from $108 million.Core laboratory revenues were $911 million, up 3 percent from $885 million in the prior-year quarter.However, diagnostics sales of $1.16 billion are reported, which is up 4 percent from $1.12 billion in Q1 2016.Īccording to the report, within Diagnostics. In general, Abbott has reported overall Q1 revenues of $6.34 billion, which is 30 percent more on a reported basis from Q1 last year. This amazing growth is driven by considerable increase in core laboratory and point-of-care sales. ![]() The company recently reported that the first quarter sales in its diagnostics business grew 4% year over year. Abbott, a global healthcare company is dedicated to providing a broad range of innovative instrument systems and tests for hospitals, reference labs, physician offices and clinics. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |